Advances in new antivirals for chronic hepatitis B.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
02 Feb 2022
02 Feb 2022
Historique:
pubmed:
5
2
2022
medline:
15
3
2022
entrez:
4
2
2022
Statut:
epublish
Résumé
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
Identifiants
pubmed: 35120358
doi: 10.1097/CM9.0000000000001994
pii: 00029330-202203050-00010
pmc: PMC8920451
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-583Informations de copyright
Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
Cornberg M, Lok AS, Terrault NA, Zoulim F. Faculty E-AHTEC. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference (double dagger). J Hepatol 2020; 72:539–557. doi: 10.1016/j.jhep.2019.11.003.
doi: 10.1016/j.jhep.2019.11.003
Association CSoIDCM, Association CSoHCM. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019) (in Chinese). J Clin Hepatol 2019; 35:2648–2669. doi: 10.3969/j.issn.1001-5256.2019.12.007.
doi: 10.3969/j.issn.1001-5256.2019.12.007
Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol 2019; 4:883–892. doi: 10.1016/S2468-1253(19)30190-6.
doi: 10.1016/S2468-1253(19)30190-6
Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol 2019; 4:227–238. doi: 10.1016/S2468-1253(18)30308-X.
doi: 10.1016/S2468-1253(18)30308-X
Wang GQ, Wang FS, Cheng J, Ren H, Zhuang H, Sun J, et al. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update (in Chinese). J Clin Hepatol 2015; 31:1941–1960. doi: 10.3969/j.issn.1001-5256.2015.12.002.
doi: 10.3969/j.issn.1001-5256.2015.12.002
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001–1010. doi: 10.1056/NEJMoa051285.
doi: 10.1056/NEJMoa051285
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011–1020. doi: 10.1056/NEJMoa051287.
doi: 10.1056/NEJMoa051287
Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422–430. doi: 10.1002/hep.23327.
doi: 10.1002/hep.23327
Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology 2014; 60: (Suppl 1): 313A–314A. doi:10.1002/hep.27486.
doi: 10.1002/hep.27486
Chan HLY, Lim YS, Seto WKW, Agarwal K, Brunetto MR, Janssen HLA, et al. Three year efficacy and safety of tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) in HBeAg-negative and HBeAg-positive patients with chronic hepatitis B. Hepatology 2018; 68: (Suppl 1): 227A–228A. doi:10.1002/hep.30257.
doi: 10.1002/hep.30257
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018; 68:672–681. doi: 10.1016/j.jhep.2017.11.039.
doi: 10.1016/j.jhep.2017.11.039
Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis 2016; 20:645–665. doi: 10.1016/j.cld.2016.06.002.
doi: 10.1016/j.cld.2016.06.002
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136:2169–2179.e4. doi: 10.1053/j.gastro.2009.03.006.
doi: 10.1053/j.gastro.2009.03.006
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459–467. doi: 10.1053/j.gastro.2008.05.031.
doi: 10.1053/j.gastro.2008.05.031
Zhang XD, Zhao LN. Perspectives in the development of new drugs against hepatitis B virus (in Chinese). J Clin Hepatol 2021; 37:993–998. doi: 10.3969/j.issn.1001-5256.2021.05.001.
doi: 10.3969/j.issn.1001-5256.2021.05.001
Yan H, Zhong GC, Xu GW, He WH, Jing ZY, Gao ZC, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049doi: 10.7554/eLife.00049.
doi: 10.7554/eLife.00049
Yan H, Liu Y, Sui J, Li W. NTCP opens the door for hepatitis B virus infection. Antiviral Res 2015; 121:24–30. doi: 10.1016/j.antiviral.2015.06.002.
doi: 10.1016/j.antiviral.2015.06.002
Schieck A, Muller T, Schulze A, Haberkorn U, Urban S, Mier W. Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. Molecules 2010; 15:4773–4783. doi: 10.3390/molecules15074773.
doi: 10.3390/molecules15074773
Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect 2018; 7:186doi: 10.1038/s41426-018-0189-8.
doi: 10.1038/s41426-018-0189-8
Wedemeyer H, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T, et al. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol 2019; 70:e81doi: 10.1016/s0618-8278(19)30141-0.
doi: 10.1016/s0618-8278(19)30141-0
Kang C, Syed YY. Bulevirtide: first approval. Drugs 2020; 80:1601–1605. doi: 10.1007/s40265-020-01400-1.
doi: 10.1007/s40265-020-01400-1
Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res 2015; 122:91–100. doi: 10.1016/j.antiviral.2015.08.005.
doi: 10.1016/j.antiviral.2015.08.005
Martinez MG, Inchauspe A, Delberghe E, Chapus F, Zoulim FJJoH. Targeting hepatitis B virus with CRISPR/Cas9 approach. J Hepatol 2020; 73:S841–S842. doi: 10.1016/S0168-8278(20)32126-7.
doi: 10.1016/S0168-8278(20)32126-7
Pan JL, Xu XY. Research progress of siRNA in reducing serum HBsAg levels in patients with chronic hepatitis B (in Chinese). Chin J Hepatol 2020; 28:179–182. doi: 10.3760/cma.j.issn.1007-3418.2020.02.017.
doi: 10.3760/cma.j.issn.1007-3418.2020.02.017
Gane E, Locarnini S, Lim TH, Strasser S, Sievert W, Cheng W, et al. Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. J Hepatol 2020; 73:570–575. doi: 10.1016/s0168-8278(20)30597-3.
doi: 10.1016/s0168-8278(20)30597-3
Gane E, Locarnini S, Lim TH, Strasser S, Sievert W, Cheng W, et al. Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors. J Hepatol 2021; 75: (Suppl 2): S289–S290. doi:10.1016/S0168-8278(21)01842-0.
doi: 10.1016/S0168-8278(21)01842-0
Man-Fung Y, Stephen L, Bruce G, Thomas S, James H, Michael B, et al. First clinical experience with RNA interference [RNAi]-based triple combination therapy in chronic hepatitis B (CHB): JNJ73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA). Hepatology International 2020; 14:21doi: 10.1007/s12072-020-10030-4.
doi: 10.1007/s12072-020-10030-4
Anglero-Rodriguez Y, Lempp F, Liebow A, Nguyen T, LeBlanc S, Kaittanis C, et al. In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus. J Hepatol 2020; 73:S865doi: 10.1016/s0168-8278(20)32173-5.
doi: 10.1016/s0168-8278(20)32173-5
Gane E, Lim Y-S, Tangkijvanich P, O’Beirne J, Lim TH, Bakardjiev A, et al. Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients. J Hepatol 2020; 73:S50–S51. doi: 10.1016/s0168-8278(20)30647-4.
doi: 10.1016/s0168-8278(20)30647-4
Gane E, Lim YS, Cloutier D, Shen L, Cathcart A, Ding X, et al. Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results. J Hepatol 2021; 75: (Suppl 2): S287–S288. doi: 10.1016/S0168-8278(21)01842-0.
doi: 10.1016/S0168-8278(21)01842-0
Yuen MF, Lim YS, Cloutier D, Shen L, Arizpe A, Pang P, et al. Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection. J Hepatol 2021; 75:S738–S739.
Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol 2012; 226:365–379. doi: 10.1002/path.2993.
doi: 10.1002/path.2993
Yuen M-F, Heo J, Jang JW, Yoon J-H, Kweon YO, Park S-J, et al. Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study. J Hepatol 2020; 73:S49–S50. doi: 10.1016/s0168-8278(20)30646-2.
doi: 10.1016/s0168-8278(20)30646-2
Huang AL, Yuan ZH, Nan YM, Yang DL, Guo JT, Li WH. Clinical cure strategies for hepatitis B: direct-acting antiviral drugs (in Chinese). Chin J Hepatol 2020; 28:640–644. doi: 10.3760/cma.j.cn501113-20200722-00408.
doi: 10.3760/cma.j.cn501113-20200722-00408
Zhao N, Jia B, Zhao H, Xu J, Sheng X, Luo L, et al. A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers. Antimicrob Agents Chemother 2019; 64:1doi: 10.1128/AAC.01686-19.
doi: 10.1128/AAC.01686-19
Zhang H, Niu JQ, Ding HY, Zhang YJ, Luo L, Li CY, et al. Analysis of factors influencing the efficacy and safety of Gls4 treatment in patients with chronic hepatitis B. Hepatology 2019; 70:429A–429A. doi:10.1002/hep.30941.
doi: 10.1002/hep.30941
Zhang M, Zhang J, Tan Y, Xin Y, Gao H, Zheng S, et al. Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study. J Hepatol 2020; 73:S878–S880. doi: 10.1016/s0168-8278(20)32197-8.
doi: 10.1016/s0168-8278(20)32197-8
Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, et al. Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731. Antimicrob Agents Chemother 2020; 64:e01463-20doi: 10.1128/AAC.01463-20.
doi: 10.1128/AAC.01463-20
Ma X, Lalezari J, Nguyen T, Bae H, Schiff ER, Fung S, et al. Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. J Hepatol 2019; 70:e130doi:10.1016/S0618-8278(19)30230-0.
doi: 10.1016/S0618-8278(19)30230-0
Yuen MF, Agarwal K, Ma XL, Nguyen T, Schiff ER, Hann HW, et al. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study. J Hepatol 2020; 73: (Suppl 1): S140doi:10.1016/S0168-8278(20)30790-X.
doi: 10.1016/S0168-8278(20)30790-X
Fung S, Sulkowski M, Lalezari J, Schiff ER, Dieterich D, Hassanein T, et al. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection. J Hepatol 2020; 73:S51–S52. doi: 10.1016/S0168-8278(20)30649-8.
doi: 10.1016/S0168-8278(20)30649-8
Sulkowski MS, Agarwal K, Fung SK, Yuen RMF, Ma XL, Lalezari JP, et al. Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients. Hepatology 2019; 70:1486A–1487A. doi: 10.1002/hep.31033.
doi: 10.1002/hep.31033
Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2017; 2:877–889. doi: 10.1016/S2468-1253(17)30288-1.
doi: 10.1016/S2468-1253(17)30288-1
Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP2139-Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection. Hepatol Commun 2021; 5:189–202. doi: 10.1002/hep4.1633.
doi: 10.1002/hep4.1633
Bazinet M, Pantea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology 2020; 158:2180–2194. doi: 10.1053/j.gastro.2020.02.058.
doi: 10.1053/j.gastro.2020.02.058
Zoulim F, Lebosse F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016; 18:109–116. doi: 10.1016/j.coviro.2016.06.004.
doi: 10.1016/j.coviro.2016.06.004
Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 2016; 64:S60–S70. doi: 10.1016/j.jhep.2016.01.028.
doi: 10.1016/j.jhep.2016.01.028
Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 2015; 6:e1694doi: 10.1038/cddis.2015.42.
doi: 10.1038/cddis.2015.42
Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol 2016; 64:S71–S83. doi: 10.1016/j.jhep.2016.01.026.
doi: 10.1016/j.jhep.2016.01.026
Mouzannar K, Liang TJ. Hepatitis B virus—recent therapeutic advances and challenges to cure. J Hepatol 2020; 73:694–695. doi: 10.1016/j.jhep.2020.04.015.
doi: 10.1016/j.jhep.2020.04.015
Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 2019; 18:827–844. doi: 10.1038/s41573-019-0037-0.
doi: 10.1038/s41573-019-0037-0
Yang HC, Kao JH. Viral hepatitis. HBV cure—can we pin our hopes on immunotherapy? Nat Rev Gastroenterol Hepatol 2015; 12:129–131. doi: 10.1038/nrgastro.2015.8.
doi: 10.1038/nrgastro.2015.8
Yu XQ, Zhang XX. Research progress in host immune response during hepatitis B virus infection. Chin Med J 2020; 133:2746–2748. doi: 10.1097/CM9.0000000000001096.
doi: 10.1097/CM9.0000000000001096
Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675–680. doi: 10.1038/90609.
doi: 10.1038/90609
Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol 2018; 37:20–36. doi: 10.1080/08830185.2017.1380200.
doi: 10.1080/08830185.2017.1380200
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215–229. doi: 10.1038/nri1573.
doi: 10.1038/nri1573
Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, et al. TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues. Gastroenterology 2018; 154:1764–1777.e7. doi: 10.1053/j.gastro.2018.01.030.
doi: 10.1053/j.gastro.2018.01.030
Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol 2015; 62:1237–1245. doi: 10.1016/j.jhep.2014.12.026.
doi: 10.1016/j.jhep.2014.12.026
Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol 2018; 68:431–440. doi: 10.1016/j.jhep.2017.10.027.
doi: 10.1016/j.jhep.2017.10.027
Luk A, Jiang Q, Glavini K, Triyatni M, Zhao N, Racek T, et al. A single and multiple ascending dose study of toll-like receptor 7 agonist (RO7020531) in Chinese healthy volunteers. Clin Transl Sci 2020; 13:985–993. doi: 10.1111/cts.12791.
doi: 10.1111/cts.12791
Hu Y, Zhang H, Wu M, Liu J, Li X, Zhu X, et al. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals. Expert Opin Investig Drugs 2021; 30:263–269. doi: 10.1080/13543784.2021.1873275.
doi: 10.1080/13543784.2021.1873275
Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, et al. Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators. Hepatology 2021; 74:55–71. doi: 10.1002/hep.31695.
doi: 10.1002/hep.31695
Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, et al. Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B. Hepatology 2021; 74:1737–1749. doi: 10.1002/hep.31795.
doi: 10.1002/hep.31795
Gane E, Dunbar PR, Brooks A, Zhao Y, Tan S, Lau A, et al. Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study. J Hepatol 2020; 73: (Suppl 1): S52doi: 10.1016/s0168-8278(20)30650-4.
doi: 10.1016/s0168-8278(20)30650-4
Janssen HLA, Lim YS, Kim HJ, Tseng CH, Coffin CS, Elkashab M, et al. Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B. J Hepatol 2021; 75: (Suppl 2): S757–S758. doi: 10.1016/S0168-8278(21)01843-2.
doi: 10.1016/S0168-8278(21)01843-2
Kosinska AD, Bauer T, Protzer U. Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol 2017; 23:75–81. doi: 10.1016/j.coviro.2017.03.011.
doi: 10.1016/j.coviro.2017.03.011
Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol 2018; 30:58–67. doi: 10.1016/j.coviro.2018.04.003.
doi: 10.1016/j.coviro.2018.04.003
Lim SG, Agcaoili J, De Souza NNA, Chan E. Therapeutic vaccination for chronic hepatitis B: a systematic review and meta-analysis. J Viral Hepat 2019; 26:803–817. doi: 10.1111/jvh.13085.
doi: 10.1111/jvh.13085
Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 2019; 157:227–241.e7. doi: 10.1053/j.gastro.2019.03.044.
doi: 10.1053/j.gastro.2019.03.044
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59:450–456. doi: 10.1016/j.jhep.2013.05.003.
doi: 10.1016/j.jhep.2013.05.003
Fernandez G, A LS, Jerez E, L EA, Freyre F, J AA, et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the Therapeutic Vaccine HeberNasvac. Euroasian J Hepatogastroenterol 2018; 8:133–139. doi: 10.5005/jp-journals-10018-1279.
doi: 10.5005/jp-journals-10018-1279
Penton-Arias E, Aguilar-Rubido JC. Cuban prophylactic and therapeutic vaccines for controlling hepatitis B. MEDICC Rev 2021; 23:21–29. doi: 10.37757/MR2021.V23.N1.6.
doi: 10.37757/MR2021.V23.N1.6
Atsmon J, Machluf N, Yayon-Gur V, Sabbah C, Spaans JN, Yassin-Rajkumar B, et al. Rapid and high seroprotection rates achieved with a tri-antigenic hepatitis B vaccine in healthy young adults: results from a phase IV study. Vaccine 2021; 39:1328–1332. doi: 10.1016/j.vaccine.2020.12.050.
doi: 10.1016/j.vaccine.2020.12.050
Ma HY, Lim TH, Leerapun A, Weltman M, Jia JD, Lim YS, et al. Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study. J Hepatol 2021; 75: (Suppl 2): S731doi: 10.1016/S0168-8278(21)01843-2.
doi: 10.1016/S0168-8278(21)01843-2
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother 2020; 16:388–399. doi: 10.1080/21645515.2019.1651141.
doi: 10.1080/21645515.2019.1651141
Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300–304. doi: 10.1038/40901.
doi: 10.1038/40901
Estornes Y, Bertrand MJ. IAPs, regulators of innate immunity and inflammation. Semin Cell Dev Biol 2015; 39:106–114. doi: 10.1016/j.semcdb.2014.03.035.
doi: 10.1016/j.semcdb.2014.03.035
Gentle IE, Moelter I, Lechler N, Bambach S, Vucikuja S, Hacker G, et al. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood 2014; 123:659–668. doi: 10.1182/blood-2013-01-479543.
doi: 10.1182/blood-2013-01-479543
Zhang X, Huang K, Zhu W, Zhang G, Chen J, Huang X, et al. AS002 – targeting inhibitor of apoptosis proteins (IAPs) enhances intrahepatic antiviral immunity to clear hepatitis B virus infection in vivo. J Hepatol 2020; 73:S5–S6. doi: 10.1016/S0168-8278(20)30572-9.
doi: 10.1016/S0168-8278(20)30572-9
Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011; 60:47–53. doi: 10.1007/s00011-010-0233-1.
doi: 10.1007/s00011-010-0233-1
Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014; 10:e1003856doi: 10.1371/journal.ppat.1003856.
doi: 10.1371/journal.ppat.1003856
Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138:682–693.e1–4. doi: 10.1053/j.gastro.2009.09.052.
doi: 10.1053/j.gastro.2009.09.052
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389:2492–2502. doi: 10.1016/S0140-6736(17)31046-2.
doi: 10.1016/S0140-6736(17)31046-2
Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol 2019; 71:900–907. doi: 10.1016/j.jhep.2019.06.028.
doi: 10.1016/j.jhep.2019.06.028
Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1:23–61. doi: 10.1146/annurev.pathol.1.110304.100230.
doi: 10.1146/annurev.pathol.1.110304.100230
Wang Q, Michailidis E, Yu Y, Wang Z, Hurley AM, Oren DA, et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations. Cell Host Microbe 2020; 28:335–349.e6. doi: 10.1016/j.chom.2020.05.010.
doi: 10.1016/j.chom.2020.05.010
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 2017; 152:1297–1309. doi: 10.1053/j.gastro.2017.02.009.
doi: 10.1053/j.gastro.2017.02.009
Hong B, Wen Y, Ying T. Recent progress on neutralizing antibodies against hepatitis B virus and its implications. Infect Disord Drug Targets 2019; 19:213–223. doi: 10.2174/1871526518666180628122400.
doi: 10.2174/1871526518666180628122400
Lee HW, Park JY, Hong T, Park MS, Ahn SH. A prospective, open-label, dose-escalation, single-center, phase 1 study for GC1102, a recombinant human immunoglobulin for chronic hepatitis B patients. Hepatology 2018; 68: (Suppl 1): 268A–269A. doi: 10.1002/hep.30257.
doi: 10.1002/hep.30257
Gupta SV, Arizpe A, Fanget MC, Dholakiya S, Shen L, Pang P, et al. Preliminary pharmacokinetics and safety in healthy volunteers of VIR-3434, a monoclonal antibody for the treatment of chronic hepatitis B infection. J Hepatol 2021; 75: (Suppl 2): S733doi: 10.1016/S0168-8278(21)01843-2.
doi: 10.1016/S0168-8278(21)01843-2
Agarwal K, Yuen MF, Wedemeyer H, Cloutier D, Shen L, Arizpe A, et al. A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection. J Hepatol 2021; 75: (Suppl 2): S288doi: 0.1016/S0168-8278(21)01842-0.
Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep 2016; 16:1243–1252. doi: 10.1016/j.celrep.2016.06.078.
doi: 10.1016/j.celrep.2016.06.078
Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med 2017; 23:327–336. doi: 10.1038/nm.4275.
doi: 10.1038/nm.4275
Koh S, Kah J, Tham CYL, Yang N, Ceccarello E, Chia A, et al. Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3. Gastroenterology 2018; 155:180–193.e6. doi: 10.1053/j.gastro.2018.03.027.
doi: 10.1053/j.gastro.2018.03.027
Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, et al. Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells. Hepatology 2020; 72:1528–1540. doi: 10.1002/hep.31503.
doi: 10.1002/hep.31503
Hu J, Tang L, Cheng J, Zhou T, Li Y, Chang J, et al. Hepatitis B virus nucleocapsid uncoating: biological consequences and regulation by cellular nucleases. Emerg Microbes Infect 2021; 10:852–864. doi: 10.1080/22221751.2021.1919034.
doi: 10.1080/22221751.2021.1919034
Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat 2019; 26:1146–1155. doi: 10.1111/jvh.13126.
doi: 10.1111/jvh.13126
Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int 2020; 40 Suppl 1:27–34. doi: 10.1111/liv.14364.
doi: 10.1111/liv.14364